Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q15118

UPID:
PDK1_HUMAN

ALTERNATIVE NAMES:
Pyruvate dehydrogenase kinase isoform 1

ALTERNATIVE UPACC:
Q15118; B2R6T1; B7Z937; D3DPD8; E9PD65; Q308M4

BACKGROUND:
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial, is key in glucose and fatty acid metabolism homeostasis. By phosphorylating the pyruvate dehydrogenase subunits, it regulates metabolite flux, down-regulates aerobic respiration, and inhibits acetyl-coenzyme A formation. Its role is vital in cellular responses to hypoxia, supporting cell proliferation under such conditions and protecting against apoptosis in response to oxidative stress.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial, unveils potential pathways for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.